Steward Health Care

steward.org

Steward Health Care is the nation’s largest private, for profit physician led health care network in the United States. Headquartered in Dallas, Texas, Steward operates 36 hospitals in the United States and the country of Malta that regularly receive top awards for quality and safety. The company employs approximately 40,000 health care professionals. The Steward network includes multiple urgent care centers and skilled nursing facilities, substantial behavioral health services, over 7,900 beds under management, and approximately 2.2 million full risk covered lives through the company's managed care and health insurance services. The total number of paneled lives within

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

news image

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

news image

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More

NEW GSK CAMPAIGN WORKS TO RAISE ADULT VACCINE AWARENESS—AND COUNTER COVID-19 SLUMP

Fiercepharma | August 27, 2020

news image

GlaxoSmithKline has a goal when it comes to vaccine awareness: Boost education enough so that when people turn 50, they recognize age-recommended vaccines as automatically as they know it's time to get a colonoscopy. To work toward that benchmark, the company debuted its first general vaccine awareness campaign in the U.S. this month. The multichannel effort keys in on life moments, with the message that they’re made possible by vaccines. The “Brought to You by Vaccines&rdq...

Read More

JAZZ PHARMACEUTICALS ANNOUNCES NEW RESEARCH COLLABORATION WITH REDX PHARMA TO DISCOVER AND DEVELOP TWO TARGETED CANCER THERAPIES

Jazz Pharmaceuticals | September 09, 2020

news image

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...

Read More
news image

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More
news image

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More
news image

NEW GSK CAMPAIGN WORKS TO RAISE ADULT VACCINE AWARENESS—AND COUNTER COVID-19 SLUMP

Fiercepharma | August 27, 2020

GlaxoSmithKline has a goal when it comes to vaccine awareness: Boost education enough so that when people turn 50, they recognize age-recommended vaccines as automatically as they know it's time to get a colonoscopy. To work toward that benchmark, the company debuted its first general vaccine awareness campaign in the U.S. this month. The multichannel effort keys in on life moments, with the message that they’re made possible by vaccines. The “Brought to You by Vaccines&rdq...

Read More
news image

JAZZ PHARMACEUTICALS ANNOUNCES NEW RESEARCH COLLABORATION WITH REDX PHARMA TO DISCOVER AND DEVELOP TWO TARGETED CANCER THERAPIES

Jazz Pharmaceuticals | September 09, 2020

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...

Read More